Robinson Miller
General
Cases192
Challenger50%
Patent Owner50%
NPE50%
Practice Areas
BiotechChemicalSoftware, Security
Top Attorneys
Elite Ratings
DCTPTABCAFC
Analytics
Lawyers
Cases
Ratings Trends
Practice Areas
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 12/23/24 | LETTER ORDER, Granting a 3-week extension to the current deadline to move for a protective order. The new deadline will be January 10, 2025; the current deadline for the parties in this matter to destroy/archive confidential discovery material as required by the Discovery Confidentiality Order (DCO) is extended to January 27, 2025. Signed by Magistrate Judge Elizabeth A. Pascal on 12/23/2024. (js) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Exclude Expert Testimony of Dr. Suter Pursuant to Fed. R. Evid. 702 by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | BRIEF in Support filed by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY re [274] MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label (CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Exclude Undisclosed Invalidity References and Objection to Magistrate Judge Clark's Ruling by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Declaration of Charles H. Chevalier, Esq., # [3] Exhibit A, # [4] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony and Septic Shock by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony and Secondary Considerations by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony on Refractory Hypotension by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Dr. Chawla by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/19/24 | Corporate Disclosure Statement by HOFFMAN-LA ROCHE INC. identifying Roche Holdings, Inc. as Corporate Parent.. (MILLER, KEITH) (Entered: 12/19/2024) |